Cambridge Cognition's Monument enters schizophrenia partnership with FNIH
Cambridge Cognition Holdings Plc said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for schizophrenia.
The AIM-traded firm said the clinical study would evaluate MT1988, a novel therapy targeting cognitive impairment associated with schizophrenia, in a proof-of-principle trial under the Accelerating Medicines Partnership Schizophrenia programme.
It said the initiative, managed by FNIH, would bring together the US National Institutes of Health, major pharmaceutical groups and non-profit organisations, with $44m committed to date.
Cambridge Cognition said schizophrenia ranks among the top 15 causes of disability worldwide, with symptoms including hallucinations, delusions and cognitive decline.
Many patients showed early signs in a "clinical high risk" phase, which currently has no effective treatment options.
It said its proprietary digital cognitive assessment tools supported the early development of MT1988 and helped establish the biomarker strategy used by Monument.
The company retains a 20% equity interest, valued at £1.8m, and future royalty rights, following Monument's spin-out in 2021.
"Monument's continued progress into patient trials is a significant step in developing precision treatments for brain health," said Rob Baker, joint managing director and chief operating officer.
"It highlights the value of Cambridge Cognition's digital assessment technology in this field and reinforces our confidence in Monument's strategy, which targets areas of high unmet clinical need and offers strong potential for long-term value through our equity and royalty interests."
At 1128 BST, shares in Cambridge Cognition Holdings were up 85 at 27p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
